| Dr Mark Edwin Lund, MD, FCCP | |
|
1331 E Wyoming Ave, Philadelphia, PA 19124-3808 | |
| (215) 537-7400 | |
| (215) 537-7193 |
| Full Name | Dr Mark Edwin Lund |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 27 Years |
| Location | 1331 E Wyoming Ave, Philadelphia, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952330300 | NPI | - | NPPES |
| 060487 | Other | ME | ANTHEM |
| 3180515 | Other | ME | AETNA HMO |
| 7006447 | Other | ME | AETNA NON HMO |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grand View Hospital | Sellersville, PA | Hospital |
| Einstein Medical Center Montgomery | East norriton, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lung Health Services Pc | 8820328974 | 4 |
News Archive
Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.
Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.
Compared to the general population, patients starting dialysis have an increased risk of death that is not attributable to a higher rate of death from cardiovascular causes, as previously thought, according to a study in the October 28 issue of JAMA.
Clinical Data, Inc. (NASDAQ: CLDA) today announced the sale of certain assets to Intrexon Corporation, a transaction that is consistent with the Company's ongoing plan to focus resources on its valuable late-stage and preclinical drug programs.
A mutant protein found in humans with colon cancer blocks a pathway that regulates proliferation and expansion of cells, increasing amounts of bacterial species associated with the development of colon cancer.
› Verified 1 days ago
| Entity Name | Montgomery County Pulmonary And Sleep Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932156791 PECOS PAC ID: 0345226247 Enrollment ID: O20040629001146 |
News Archive
Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.
Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.
Compared to the general population, patients starting dialysis have an increased risk of death that is not attributable to a higher rate of death from cardiovascular causes, as previously thought, according to a study in the October 28 issue of JAMA.
Clinical Data, Inc. (NASDAQ: CLDA) today announced the sale of certain assets to Intrexon Corporation, a transaction that is consistent with the Company's ongoing plan to focus resources on its valuable late-stage and preclinical drug programs.
A mutant protein found in humans with colon cancer blocks a pathway that regulates proliferation and expansion of cells, increasing amounts of bacterial species associated with the development of colon cancer.
› Verified 1 days ago
| Entity Name | Lung Health Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063076289 PECOS PAC ID: 8820328974 Enrollment ID: O20191002003199 |
News Archive
Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.
Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.
Compared to the general population, patients starting dialysis have an increased risk of death that is not attributable to a higher rate of death from cardiovascular causes, as previously thought, according to a study in the October 28 issue of JAMA.
Clinical Data, Inc. (NASDAQ: CLDA) today announced the sale of certain assets to Intrexon Corporation, a transaction that is consistent with the Company's ongoing plan to focus resources on its valuable late-stage and preclinical drug programs.
A mutant protein found in humans with colon cancer blocks a pathway that regulates proliferation and expansion of cells, increasing amounts of bacterial species associated with the development of colon cancer.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Edwin Lund, MD, FCCP 1331 E Wyoming Ave, Philadelphia, PA 19124-3808 Ph: (215) 537-7400 | Dr Mark Edwin Lund, MD, FCCP 1331 E Wyoming Ave, Philadelphia, PA 19124-3808 Ph: (215) 537-7400 |
News Archive
Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.
Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.
Compared to the general population, patients starting dialysis have an increased risk of death that is not attributable to a higher rate of death from cardiovascular causes, as previously thought, according to a study in the October 28 issue of JAMA.
Clinical Data, Inc. (NASDAQ: CLDA) today announced the sale of certain assets to Intrexon Corporation, a transaction that is consistent with the Company's ongoing plan to focus resources on its valuable late-stage and preclinical drug programs.
A mutant protein found in humans with colon cancer blocks a pathway that regulates proliferation and expansion of cells, increasing amounts of bacterial species associated with the development of colon cancer.
› Verified 1 days ago
Philippe Olivier Szapary, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3400 Civic Center Blvd, East Pavilion, 2nd Floor, Philadelphia, PA 19104 Phone: 215-615-4949 | |
Dr. Jamie L. Garfield, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-5864 Fax: 215-707-6867 | |
Maria Esther Escorcia De Leon, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-1622 Fax: 215-707-0943 | |
Cherag Daruwala, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2301 E Allegheny Ave, Suite 190b, Philadelphia, PA 19134 Phone: 215-926-3120 Fax: 215-926-3123 | |
Dr. Robert Burke, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 51 N 39th St, Philadelphia, PA 19104 Phone: 215-662-9436 Fax: 215-243-3208 | |
Eva Hassan Alsheik, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 219 N Broad St, 5th Floor, Philadelphia, PA 19107 Phone: 215-762-6071 | |
Dr. Jason Thomas Ackrivo, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3400 Spruce St, Philadelphia, PA 19104 Phone: 215-614-0871 |